AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05180539 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Condition
Description: Two-session in person group discussions focusing on college health behaviors
Study NCT05720637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
Study NCT05720637 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: SSRI
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
Study NCT05720637 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SSRI
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
Study NCT05720637 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SIA
Description: This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
Study NCT05720637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIA
Description: This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
Study NCT04101292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Characterization of tumor tissue by fluorescence
Description: * HSI Imaging of the resected specimen, from the serum and the mucous side~* FF-OCT imaging of the tumor and the healthy tissue biopsies~* Local application of Bevacizumab-IRDye800CW and visualization with the Surgvision Explorer system~* Standard anti-VEGF Immunohistochemistry and pathology
Study NCT06446934 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: Initial CPAP titration and subsequent CPAP therapy for 12 weeks
Study NCT04816916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXA1665
Description: AXA1665 administered TID with food
Study NCT04816916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered TID with food
Study NCT04682899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procalcitonin-guided antibiotic therapy
Description: In procalcitonin group, clinican make a decision of antibiotic precription based on the results of procalcitonin.
Study NCT04682899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guideline-guided antibiotic therapy
Description: In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
Study NCT05648903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total diet replacement
Description: The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly to 12 months. The TDR products will be provided to participants free of charge. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks but participants would have to self-fund these products.
Study NCT06224127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active heat
Description: Users receive an active Soovu heating pod(s).
Study NCT06224127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active c tactile fiber stimulation
Description: Hair brushes that activate c tactile fibers
Study NCT06224127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham heat
Description: A Soovu heating pod(s) in the subtherapeutic temperature range
Study NCT06224127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham c tactile fiber stimulation
Description: Hair brushes that do not activate c tactile fibers
Study NCT05737862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera capsules
Description: In this arm, pregnant mothers receive capsules containing 500 mg of powdered Moringa oleifera leaves which contain 13.09 mg of iron per100 gram. Dose: 2 × 2 capsules per day for 30 days
Study NCT05648903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Description: Participants who choose this intervention will be supported to undertake a low-carbohydrate diet. During the first 12 weeks of the programme patients will be supported to consume below 100g carbohydrate per day, whilst being encouraged to increase protein, choose predominantly unsaturated fats alongside a high intake of non-starchy vegetables and low-carbohydrate fruits. After 12 weeks patients will be able to increase their carbohydrate intake up to 130g per day. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 100g carbohydrate for an additional 4 weeks.
Study NCT05648903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 5:2
Description: Participants will have the option to follow a 5:2 dietary approach whereby calories are significantly reduced on two days of the week to 500 calories per day for women and 600 calories per day for men. The placement of the fasting days can vary each week, but there must be two fasting days in each seven-day period. After 12 weeks, patients will have the option of continuing with the 5:2 approach for further weight loss or adopting a 6:1 approach whereby patients would only fast on 1 day in each seven-day cycle for weight maintenance. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 5:2 approach for an additional 4 weeks.
Study NCT04723459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin impregnated mask
Description: mask with ivermectin nano solution
Study NCT05732376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nasopharyngoscopic Velopharyngeal Training with 3D Printed Endoscopy Training Model
Description: Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the 3D printed endoscopy training model. Participants will receive hands-on training on the 3D printed endoscopy training model, under the guidance of the principal investigator.
Study NCT05732376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngoscopic Velopharyngeal Training with Ready-Made Endoscopy Training Model
Description: Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the ready-made endoscopy training model. Participants will receive hands-on training on the ready-made endoscopy training model, under the guidance of the principal investigator.
Study NCT05739318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The cuff of endotracheal and endobronchial is collapsed
Description: The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is collapsed as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
Study NCT05739318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The cuff of endotracheal and endobronchial is inflated
Description: The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is inflated as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
Study NCT06216418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRFS-18G-S100WH
Description: A facial tissue fixation material made of polydioxanone (PDO).
Study NCT06216418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MINT Lift FINE+
Description: A facial tissue fixation material made of polydioxanone (PDO).
Study NCT05737862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron and folic acid supplements
Description: In this arm, pregnant mothers receive IFA tablets 2 × 1 tablet a day for 30 days. Each IFA tablet contains 400 mcg folic acid and 180 mg Ferrous Fumarate.
Study NCT05737862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron and folic acid supplements
Description: In this arm, pregnant mothers receive IFA tablets 2 × 1 tablet a day for 30 days. Each IFA tablet contains 400 mcg folic acid and 180 mg Ferrous Fumarate.
Study NCT05294861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YesMdiet
Description: In the YesMdiet, participants will consume Milk and Dairy products
Study NCT05294861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NoMdiet
Description: In the YesMdiet, participants will not consume Milk and Dairy products, only other sources of protein
Study NCT06086379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training for COVID-19
Description: CCT-C is a manualized group-based behavioral intervention (10 weeks, 2 hours per week, 20 hours total) designed to improve cognition and everyday functioning in patients with prolonged COVID-19 symptoms
Study NCT06086379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Holistic Cognitive Education
Description: HCE provides the same frequency and amount of therapist and other group member contact as CCT-C, but does not provide training in cognitive or lifestyle strategies addressed in CCT-C. The HCE intervention provides information and discussion regarding common causes of and treatments for cognitive impairment.
Study NCT05265702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 12 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
Study NCT05606601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minder
Description: There are four main components of the Minder app: The Chatbot, Services, Community, and Peer Coaching components. The Services component asks participants to complete a series of questions on various mental health, substance use, and general life issues. It then recommends community and on-campus resources based on their current needs. The Community component of the app matches individuals with groups (e.g., student clubs) and events at the university or in the broader community that they may be interested in. The Chatbot component of the app contains pre-formatted conversational scripts that users engage with via a chatbot and videos designed to teach evidence-based skills (e.g., cognitive strategies to manage anxiety) that can be applied to everyday life. To support use of the app, all users in the intervention group will be offered access to trained peer coaches to help users navigate the different app components and provide non-clinical peer support.
Study NCT05455034 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: single-cell sequencing
Description: Treatment is given according to the results of single-cell sequencing.
Study NCT05804318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily adaptive SBRT with urethral sparing
Description: The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.
Study NCT06330376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care of traditional treatment
Description: Usual care of traditional treatment which is PT and/or OT when indicated Followed by Pulmonary rehabilitation when indicated
Study NCT06330376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific DB program/Diaphragmatic manipulation program
Description: 12 weeks of 2 sessions/week: one session will be remote and one in-person
Study NCT05824598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifunctional rehabilitation treatment
Description: multidisciplinary approach with (OMT, psychological counseling, and therapists dedicated to swallowing disorders)
Study NCT04690465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Participants will receive a 16-week resistance training program, with 3 times a week (a total of 48 training sessions) and 60 minutes per session intervention, which is adopted from the 12-week resistance training program introduced in the book Growing Stronger: Strength Training for Older Adults (Seguin et al., 2002), with minor modifications under the advice of Physical Fitness Association of Hong Kong, China (PFA).
Study NCT04690465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eight-form Yang-style Tai Chi program
Description: The active concurrent control group will receive Eight-form Yang-style Tai Chi program which has been confirmed feasible and will be taught by the qualified coach.
Study NCT05091177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test,thymus CT, low frequency repeated nerve stimulation
Description: Use relevant instruments for inspection
Study NCT01938196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711
Study NCT01938196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05222880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3
Description: TEST Lens
Study NCT01244074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biofeedback training
Study NCT05401565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
Study NCT05401565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT06108999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connettivina BIO cream and gauze
Description: Connettivina Bio cream and gauze-pad efficacy and tolerability will be evaluated in the management of acute or chronic wounds of different etiology, according to instruction for use. Only one wound per patient will be considered for the treatment according to the study protocol. The schedule treatment will consist on a daily medication changes, according to the instruction for use and the clinical practice, for a maximum of 7 Visits.
Study NCT05344846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided imagery
Description: The individuals in this group will be provided with guided imagery application. Guided imagery will be applied to the participants in the hospital environment 6-10 hours after the cesarean section. Afterwards, guided imagery application will be requested every day for two weeks.
Study NCT00433472 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: magnetic resonance imaging (MRI)
Description: MRI scan to be complete to look at RSR13 on measurement of T2 and T2\* on MRI
Study NCT03167554 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
Study NCT03167554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 1
Description: Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.
Study NCT03167554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 2
Description: Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.
Study NCT05446961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LCLT : 68% elemental L-carnitine and 32 % Tartric acid
Description: 3 g orally capsules
Study NCT05446961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally capsules
Study NCT06085521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001 Dose A
Description: Capsules taken orally
Study NCT06433453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 MG
Description: The medication is commenced when a preovulatory follicle is observed. It will be administered for a minimum of one day, up to a maximum of 7 days. It will be discontinued when anovulation is observed.
Study NCT06433453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound scans
Description: Ultrasound scans done intermittently before and after an ovulatory or anovulatory event
Study NCT06433453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finger prick blood test
Description: Capillary blood extracted from a finger prick. Blood spots are collected on a specialized card, dried and frozen before reproductive hormones are assayed from them.
Study NCT06433453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine test
Description: Early morning urine tests to assay reproductive hormones
Study NCT04842487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)
Description: Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
Study NCT06085521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001 Dose B
Description: Capsules taken orally
Study NCT06085521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules taken orally
Study NCT06209073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality exercise
Description: after explaining the treatment method for patients, the patients will perform full body aerobic exercise by applying kick boxing to destroy walls of rock; the patient moves most of body muscles in this game. He or she flex and extend the shoulder and the elbow with flexion and extension in the knee. squatting exercise, endurance exercise, coordination for arm and shoulder exercise will also performed in virtual reality
Study NCT05749172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength group
Description: 4 sets of strength training exercises with 10 repetitions determined from ACSM two days a week, with a minimum of 72 hours between these days. In this exercise protocol, the movements of back squat, seated leg extension, seated leg curls, machine hip adductions, machine hip abductions, standing calf raises, back lat pulldowns, seated rows, bench press, incline bench press, biceps curls, triceps pushdowns, back press, back extension, pushup, pullup, squats and sit-ups will be performed.
Study NCT05749172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled group
Description: Two hours of parkour training for two days a week.
Study NCT06209073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive conventional treatment in the form of aerobic exercise, resistance exercise and endurance exercise.
Study NCT05357846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg, IV (in the vein) on day 1 and day 22